Please login to the form below

Not currently logged in
Email:
Password:

Stemcentrx

This page shows the latest Stemcentrx news and features for those working in and with pharma, biotech and healthcare.

AbbVie slumps on trial results for would-be blockbuster Rova-T

AbbVie slumps on trial results for would-be blockbuster Rova-T

It was the main asset in the pharma group’s $10bn acquisition of Stemcentrx in 2016.

Latest news

  • Trial of AbbVie's Rova-T disappoints at ASCO Trial of AbbVie's Rova-T disappoints at ASCO

    Rova-T was the centrepiece of AbbVie's acquisition of Stemcentrx, which closed last week and has been seen as an important piece in the company's attempts to build a ... The reception to the data seems to reflect the high expectations for the drug, which

  • AbbVie adds to cancer portfolio with $9.8bn Stemcentrx deal AbbVie adds to cancer portfolio with $9.8bn Stemcentrx deal

    AbbVie adds to cancer portfolio with $9.8bn Stemcentrx deal. Continues to build its oncology business to lessen its reliance on Humira. ... AbbVie capped off a buoyant first quarter performance with a deal to buy Stemcentrx, the latest in a string of

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Stemcentrx represents a good fit with AbbVie's oncology portfolio and is forecast to generate multibillion $revenue. ... Not content with the Stemcentrx acquisition, in April AbbVie also closed two other oncology deals:.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics